Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
DCTH's Cash to Debt is ranked higher than
98% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. DCTH: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DCTH' s Cash to Debt Range Over the Past 10 Years
Min: 1.97  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.69
DCTH's Equity to Asset is ranked higher than
60% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DCTH: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
DCTH' s Equity to Asset Range Over the Past 10 Years
Min: 0.61  Med: 0.76 Max: 0.84
Current: 0.69
0.61
0.84
Interest Coverage No Debt
DCTH's Interest Coverage is ranked higher than
97% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.03 vs. DCTH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
DCTH' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -18.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -891.63
DCTH's Operating margin (%) is ranked lower than
95% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. DCTH: -891.63 )
Ranked among companies with meaningful Operating margin (%) only.
DCTH' s Operating margin (%) Range Over the Past 10 Years
Min: -15569.65  Med: -4179.62 Max: -1805.8
Current: -891.63
-15569.65
-1805.8
Net-margin (%) -784.63
DCTH's Net-margin (%) is ranked lower than
95% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. DCTH: -784.63 )
Ranked among companies with meaningful Net-margin (%) only.
DCTH' s Net-margin (%) Range Over the Past 10 Years
Min: -14990.75  Med: -3838.48 Max: -1625.91
Current: -784.63
-14990.75
-1625.91
ROE (%) -76.66
DCTH's ROE (%) is ranked lower than
92% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. DCTH: -76.66 )
Ranked among companies with meaningful ROE (%) only.
DCTH' s ROE (%) Range Over the Past 10 Years
Min: -224.96  Med: -108.90 Max: -29.56
Current: -76.66
-224.96
-29.56
ROA (%) -57.46
DCTH's ROA (%) is ranked lower than
93% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. DCTH: -57.46 )
Ranked among companies with meaningful ROA (%) only.
DCTH' s ROA (%) Range Over the Past 10 Years
Min: -157.86  Med: -80.87 Max: -27.27
Current: -57.46
-157.86
-27.27
ROC (Joel Greenblatt) (%) -845.54
DCTH's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. DCTH: -845.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DCTH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -194983.33  Med: -1334.70 Max: -161.78
Current: -845.54
-194983.33
-161.78
EBITDA Growth (3Y)(%) -43.20
DCTH's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. DCTH: -43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DCTH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.2  Med: -1.60 Max: 56.5
Current: -43.2
-43.2
56.5
EPS Growth (3Y)(%) -44.80
DCTH's EPS Growth (3Y)(%) is ranked lower than
93% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. DCTH: -44.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DCTH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.8  Med: -7.45 Max: 93.9
Current: -44.8
-44.8
93.9
» DCTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

DCTH Guru Trades in Q4 2014

Jim Simons 260,960 sh (+61.29%)
» More
Q1 2015

DCTH Guru Trades in Q1 2015

Jim Simons 345,098 sh (+32.24%)
» More
Q2 2015

DCTH Guru Trades in Q2 2015

Jim Simons 504,213 sh (+46.11%)
» More
Q3 2015

DCTH Guru Trades in Q3 2015

Jim Simons 617,898 sh (+22.55%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.45
DCTH's P/B is ranked higher than
96% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.54 vs. DCTH: 0.45 )
Ranked among companies with meaningful P/B only.
DCTH' s P/B Range Over the Past 10 Years
Min: 0.38  Med: 1.09 Max: 6.18
Current: 0.45
0.38
6.18
P/S 2.32
DCTH's P/S is ranked higher than
56% of the 929 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. DCTH: 2.32 )
Ranked among companies with meaningful P/S only.
DCTH' s P/S Range Over the Past 10 Years
Min: 2.22  Med: 38.17 Max: 1077.33
Current: 2.32
2.22
1077.33
EV-to-EBIT 0.73
DCTH's EV-to-EBIT is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.42 vs. DCTH: 0.73 )
Ranked among companies with meaningful EV-to-EBIT only.
DCTH' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.7  Med: -0.10 Max: 0.8
Current: 0.73
-2.7
0.8
EV-to-EBITDA 0.78
DCTH's EV-to-EBITDA is ranked higher than
99% of the 852 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. DCTH: 0.78 )
Ranked among companies with meaningful EV-to-EBITDA only.
DCTH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.8  Med: -0.10 Max: 0.8
Current: 0.78
-2.8
0.8
Current Ratio 3.51
DCTH's Current Ratio is ranked higher than
68% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. DCTH: 3.51 )
Ranked among companies with meaningful Current Ratio only.
DCTH' s Current Ratio Range Over the Past 10 Years
Min: 0.58  Med: 7.01 Max: 67.13
Current: 3.51
0.58
67.13
Quick Ratio 3.43
DCTH's Quick Ratio is ranked higher than
74% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. DCTH: 3.43 )
Ranked among companies with meaningful Quick Ratio only.
DCTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 7.01 Max: 67.13
Current: 3.43
0.58
67.13
Days Inventory 301.25
DCTH's Days Inventory is ranked lower than
93% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. DCTH: 301.25 )
Ranked among companies with meaningful Days Inventory only.
DCTH' s Days Inventory Range Over the Past 10 Years
Min: 669.79  Med: 717.41 Max: 5170.83
Current: 301.25
669.79
5170.83
Days Sales Outstanding 98.55
DCTH's Days Sales Outstanding is ranked lower than
66% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. DCTH: 98.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
DCTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.41  Med: 151.91 Max: 161.25
Current: 98.55
59.41
161.25
Days Payable 182.50
DCTH's Days Payable is ranked higher than
87% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. DCTH: 182.50 )
Ranked among companies with meaningful Days Payable only.
DCTH' s Days Payable Range Over the Past 10 Years
Min: 457.82  Med: 938.21 Max: 8788.08
Current: 182.5
457.82
8788.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.57
DCTH's Price/Net Cash is ranked higher than
99% of the 284 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.02 vs. DCTH: 0.57 )
Ranked among companies with meaningful Price/Net Cash only.
DCTH' s Price/Net Cash Range Over the Past 10 Years
Min: 0.79  Med: 6.25 Max: 62.95
Current: 0.57
0.79
62.95
Price/Net Current Asset Value 0.50
DCTH's Price/Net Current Asset Value is ranked higher than
98% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. DCTH: 0.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DCTH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.72  Med: 5.76 Max: 44.4
Current: 0.5
0.72
44.4
Price/Tangible Book 0.45
DCTH's Price/Tangible Book is ranked higher than
97% of the 889 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. DCTH: 0.45 )
Ranked among companies with meaningful Price/Tangible Book only.
DCTH' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.65  Med: 4.77 Max: 44.06
Current: 0.45
0.65
44.06
Price/Median PS Value 0.06
DCTH's Price/Median PS Value is ranked higher than
99% of the 899 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. DCTH: 0.06 )
Ranked among companies with meaningful Price/Median PS Value only.
DCTH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.02 Max: 22.96
Current: 0.06
0.09
22.96
Earnings Yield (Greenblatt) (%) 135.19
DCTH's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DCTH: 135.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DCTH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 132.38  Med: 242.90 Max: 8318.4
Current: 135.19
132.38
8318.4

More Statistics

Revenue(Mil) $2
EPS $ -1.05
Beta1.13
Short Percentage of Float7.67%
52-Week Range $0.25 - 1.92
Shares Outstanding(Mil)21.76

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 6 16
EPS($) -0.10 0.01
EPS without NRI($) -0.10 0.01

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DV3.Germany,
Delcath Systems Inc is a Delaware corporation, incorporated on August 5, 1988. The Company is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. It is a specialty pharmaceutical and medical device company developing its proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, its proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Its primary focus is on the execution of its clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. Its competitors include Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others. The Company currently holds seven United States patents, ten foreign patents with patent validity in 15 countries, four pending United States patent applications, and two pending foreign patent applications. The Company's products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.
» More Articles for NAS:DCTH

Headlines

Articles On GuruFocus.com
Five NCAV Companies for Value Investors – August 2015 Aug 04 2015 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
Delcath Systems to Present at Upcoming Investor Conferences Feb 04 2016
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 22 2016
Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic... Jan 20 2016
Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic... Jan 20 2016
MicroCap Review Magazine Winter/Spring 2016 Issue Now Available Jan 19 2016
Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic... Jan 19 2016
Delcath To Present At NobleCon12 Investor Conference Jan 15 2016
Delcath To Present At NobleCon12 Investor Conference Jan 15 2016
Review of Delcath Melphalan/HDS System Published in "Cardiovascular & Interventional Radiology" Jan 11 2016
Delcath Prior Phase 3 Trial Results Published In Annals Of Surgical Oncology Dec 09 2015
DELCATH SYSTEMS, INC. Financials Dec 08 2015
Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional... Dec 08 2015
Delcath Announces CHEMOSAT Treatment Milestones In Europe Dec 02 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 25 2015
Delcath Systems Inc Conference Call to discuss Business Update scheduled for 10:00 am ET today Nov 17 2015
Delcath Systems To Host Business Update Conference Call On November 17, 2015 Nov 11 2015
Delcath Systems To Host Business Update Conference Call On November 17, 2015 Nov 11 2015
DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2015
Delcath Reports 2015 Third Quarter Financial Results Nov 10 2015
Delcath Reports 2015 Third Quarter Financial Results Nov 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK